Patents Assigned to Transgenion—International Institute for Regenerative Translational Medicine GmbH
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 11124835
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene DMBT1 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene DMBT1 and optionally one or more further marker genes selected from KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 21, 2021
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10604806
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene KIAA1199 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene KIAA1199 and optionally one or more further marker genes selected from DMBT1, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAMS, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 31, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10538810
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene KIAA1199 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene KIAA1199 and optionally one or more further marker genes selected from DMBT1, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAMS, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: January 21, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10526656
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene TMSB15A is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene TMSB15A and optionally one or more further marker genes selected from DMBT1, KIAA1 T99, DPP6, SLC51 B, NUDT1 1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR1 10, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1 B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: January 7, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10508307
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene DMBT1 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene DMBT1 and optionally one or more further marker genes selected from KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 17, 2019
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche